In a preliminary release ahead of its full report on 24 October 2025, AVTECH announced Q3 2025 net s...
Redeye is positive about Corline’s and Kardium’s development with a new ten-year agreement, and that...
Redeye comments on the termination of “Project Baxter”, which we believe was the right decision give...
Redeye is optimistic after Hansa’s directed share issue tonight, which was expanded from USD60m to U...
Redeye retains its SEK394 Base Case in Lime, leaving notable upside potential given the recent soft ...
Redeye provides a short comment on the recently announced Q3 sales figure from Scandinavian ChemoTec...
* Report out on 17 October * Q3e sales SEK 48m, EBIT SEK -0.
Redeye is positive about Corline’s new licensing and supply agreement with Kardium, which underlines...
* Byggmästaren proposes extraordinary dividend and share split * Updates dividend policy and reaffir...
Redeye comments on Heliospectra’s proposed SEK49.5m rights issue, partly secured by main shareholder...
* Q3'25 numbers due on 5 November at 07:45 CET * Adj.
* We forecast 7% EBITA growth in Q3'25 * M&A could add 30-40% to '27e EBITA * We raise our fair valu...
Redeye comments on Invisio’s announcement of a 10-year contract with US Coast Guard regarding wirele...
The preliminary US ConfIdes results confirms that Kidney transplants supported by Imlifidase preserv...
Redeye leaves Addnode’s CMD with a positive impression, as the company’s ambition for growth and mar...
